Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338
This study is recruiting at 9 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumors
- Metastatic Solid Tumors
- Non-small Cell Lung Cancer (NSCLC)
- NSCLC
- Colorectal Cancer (CRC)
- CRC
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Revolution Medicines, Inc.
- Last updated on ClinicalTrials.gov
- August 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- USC Norris Comprehensive Cancer Center · Los Angeles, CA
Connecticut · 1
- Eastern Connecticut Hematology and Oncology Associates · Norwich, CT
Minnesota · 1
- Health Partners Cancer Center at Regions Hospital · Saint Paul, MN
Tennessee · 1
- Tennessee Oncology · Nashville, TN
Texas · 4
- MD Anderson Cancer Center · Houston, TX
- MD Anderson Cancer Center · Houston, TX
- NEXT Dallas · Irving, TX
- NEXT Oncology · San Antonio, TX
Virginia · 1
- NEXT Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.